1. Report Overview

1.1 Overview of the World Vaccines Market

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Main Questions Answered by This Analytical Study

1.5 Who is This Report For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to the World Human Vaccines Market

2.1 Human Vaccines - Aiming for Global Disease Prevention

2.2 What is the Social and Economic Burden?

2.3 Vaccine Technology

2.3.1 Inactivated Vaccines

2.3.2 Live Attenuated Vaccines

2.3.3 Conjugate Vaccines

2.3.4 Recombinant Vector Vaccines

2.4 Key Influencers of the Human Vaccine Market

2.4.1 Governments and International Organizations

2.4.1.1 The World Health Organisation (WHO)

2.4.1.2 The Governmental Influence

2.4.2 Leading Manufacturers

2.4.2.1 Merck& Co.

2.4.2.2 Sanofi

2.4.2.3 GlaxoSmithKline

2.4.2.4 Pfizer

2.5 Human World Vaccines – Market Segmentation

2.5.1 Paediatric Vaccines

2.5.2 Adult Vaccines

2.5.3 Elderly Vaccines

2.5.4 Travel Vaccines

2.5.5 Therapeutic Vaccines

3. World Vaccine Market Outlook, 2019-2029

3.1 World Vaccine Market, 2018

3.1.1 Paediatric Vaccines Maintains Constant Demand

3.1.2 Ageing Population Requires More Care

3.1.3 Emerging Markets Demand Better Immunity

3.2 The World Human Vaccines Forecast, 2019-2029

3.3 The World Vaccine Market: Industry Trends

3.3.1 Undulating Demand

3.3.2 Supply Restraints

3.3.3 Funding Trends

3.3.4 Protecting the Workforce of an Economy

4. World Vaccine Submarkets: Prospects, 2019-2029

4.1 Paediatric Vaccines

4.1.1 Paediatric Vaccine Forecast, 2019-2029

4.1.2 Paediatric Vaccine Trends

4.1.2.1 Innovative Delivery

4.1.2.2 Fear Factor

4.1.2.3 Novel Vectors

4.2 Adult Vaccines

4.2.1 Adult Vaccine Forecast, 2019-2029

4.2.2 Adult Vaccine Trends

4.2.2.1 Fighting the Flu

4.2.2.2 HPV

4.2.2.3 Repeat Doses for Continued Protection

4.3 Elderly Vaccines

4.3.1 Elderly Vaccine Forecast, 2019-2029

4.3.2 Elderly Vaccine Trends

4.3.2.1 With Age Comes Greater Risk

4.3.2.2 Ageing Population across the Globe

4.4 Travel Vaccines

4.4.1 Travel Vaccines Forecast, 2018-2029

4.4.2 Travel Vaccine Trends

4.4.2.1 Zika Virus Outbreak

4.4.2.2 Globalization Carries Diseases

4.5 Therapeutic Vaccines

4.5.1 Therapeutic Vaccine Trends

5. Leading Vaccines: Revenue Forecasts, 2019-2029

5.1 Prevnar (Pfizer) - Pneumococcal Pneumonia

5.2 Gardasil (Merck & Co.) - HPV

5.3 Fluzone (Sanofi) – Influenza

5.4 Pentacel (Sanofi) – DtaP, Polio, HiB

5.5 ProQuad / M-M-R II / Varivax (Merck and Co.) – Varicella/Chickenpox, Measles, Mumps, Rubella.

5.6 Infanrix/Pediarix (GSK) – Diptheria, Tetanus and Acellular Pertussis

5.7 Zostavax (Merck and Co.) – Herpes

5.8 RotaTeq (Merck and Co.) – Rotavirus

5.9 Hepatitis Vaccines (GSK) – Hepatitis A & B

5.10 Menactra (Sanofi) – Meningococcal

6. Regional and Leading Developed National Vaccines Markets, 2019-2029

6.1 North America Vaccine Market, 2019-2029

6.1.1 The US Vaccine Market, 2018

6.1.2 The US Vaccine Market Forecast, 2019-2029

6.2 Japanese Vaccine Market, 2019-2029

6.2.1 The Japanese Vaccine Market, 2018

6.2.2 The Japanese Vaccine Market Forecast, 2019-2029

6.2.3 Addressing the Alleged Vaccine Gap

6.3 EU5 Vaccine Market, 2019-2029

6.3.1 The EU5 Vaccine Market, 2018

6.3.2 The EU5 Vaccine Market Forecast, 2019-2029

6.4 United Kingdom Vaccine Market, 2019-2029

6.4.1 The UK Vaccine Market, 2018

6.4.2 The UK Vaccine Market Forecast, 2019-2029

6.5 France: Vaccine Market, 2019-2029

6.5.1 The French Vaccine Market, 2018

6.5.2 The French Vaccine Market Forecast, 2019-2029

6.5.3 French Healthcare System – Immunization Policy

6.6 Germany: Vaccine Market, 2019-2029

6.6.1 The German Vaccine Market, 2018

6.6.2 The German Vaccine Market Forecast, 2019-2029

6.7 Italy: Vaccine Market, 2019-2029

6.7.1 The Italian Vaccine Market, 2018

6.7.2 The Italian Vaccine Market Forecast, 2019-2029

6.7.3 Challenges in Public Healthcare

6.8 Spain: Vaccine Market, 2019-2029

6.8.1 The Spanish Vaccine Market, 2018

6.8.2 The Spanish Vaccine Market Forecast, 2019-2029

6.8.3 District Rules – Economic Challenges

7. Leading Emerging National Markets, 2019-2029

7.1 China: Vaccine Market, 2019-2029

7.1.1 The Chinese Vaccine Market, 2018

7.1.2 The Chinese Vaccine Market Forecast, 2019-2029

7.1.3 Setting-Up Domestic Vaccine Industries

7.2 India: Vaccine Market, 2019-2029

7.2.1 The Indian Vaccine Market, 2018

7.2.2 The Indian Vaccine Market Forecast, 2019-2029

7.2.3 The Extent to which the Vaccine Market Can Flourish?

7.3 Brazil: Vaccine Market, 2019-2029

7.3.1 The Brazilian Vaccine Market, 2018

7.3.2 The Brazilian Vaccine Market Forecast, 2019-2029

7.3.3 Zika Outbreak

7.4 Russia: Vaccine Market, 2019-2029

7.4.1 The Russian Vaccine Market, 2018

7.4.2 The Russian Vaccine Market Forecast, 2019-2029

7.4.3 Power of the State

8. Leading Manufacturers of Vaccines for Human Use

8.1 GlaxoSmithKline (GSK)

8.1.1 GSK Vaccine Performance

8.1.2 GSK Developments

8.1.2.1 Mergers and Acquisitions

8.1.2.2 GSK Vaccine Pipeline

8.2 Merck& Co.

8.2.1 Merck Vaccine Performance

8.2.2 Merck Developments

8.2.2.1 Merck Market Movements

8.2.2.2 Collaborations

8.2.2.3 Merck Pipeline

8.3 Sanofi

8.3.1 Sanofi Vaccine Performance

8.3.2 Sanofi Developments

8.3.2.1 Acquisitions & Expansions

8.3.2.2 Sanofi Vaccine Pipeline

8.4 Pfizer

8.4.1 Pfizer Vaccine Performance

8.4.1.1 Financial Overview

8.4.2 Pfizer Developments

8.4.2.1 Pfizer Mergers & Acquisitions

8.4.2.2 Pfizer Pipeline

8.5 Johnson & Johnson

8.5.1 Financial Overview

8.6 AstraZeneca

8.6.1 Financial Overview

8.7 Eli Lilly and Company

8.7.1 Eli Lilly and Company Vaccine Performance

8.7.1.1 Financial Overview

8.7.2 Eli Lilly and Company Developments

8.8 Takeda Pharmaceutical Company Limited

8.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance

8.8.1.1 Financial Overview

8.9 Serum Institute of India Private Limited

8.9.1 Serum Institute of India Private Limited Vaccine Performance

8.10 Emergent BioSolutions Inc.

8.10.1 Emergent BioSolutions Inc. Vaccine Performance

8.11 Key Strategic Acquisitions and Collaborations

8.12 Other Companies Serving the Vaccines Market

9. Research & Development, 2018

9.1 Prophylactic Vaccines R&D Pipeline

9.1.1 Paediatric Vaccines R&D Pipeline

9.1.2 Adult Vaccines R&D Pipeline

9.1.3 Elderly Vaccines R&D Pipeline

9.1.4 Travel Vaccines R&D Pipeline

9.2 Therapeutic Vaccines R&D Pipeline

10. Qualitative Analysis of the World Vaccines Market

10.1 SWOT Analysis of the World Human Vaccines Market

10.1.1 Strengths

10.1.1.1 Ageing Population

10.1.1.2 Prevention is Better than Cure

10.1.1.3 Demand from Emerging Markets Continue

10.1.1.4 Promising R&D Pipeline

10.1.1.5 Increasing Awareness

10.1.2 Weaknesses

10.1.2.1 High Manufacturing Costs

10.1.2.2 Time Constraints

10.1.2.3 Barriers to Market Entry

10.1.3 Opportunities

10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods

10.1.3.2 Shifting Focus on Adults Vaccines

10.1.4 Threats

10.1.4.1 Oligarchic Presence of Pharmaceutical Giants

10.1.4.2 Productivity Gap

10.2 STEP Analysis of the World Human Vaccines Industry and Market

10.2.1 Social Factors

10.2.1.1 Maintaining a Healthier Workforce

10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects

10.2.2 Technological Forces

10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics

10.2.3 Economic Factors

10.2.3.1 High Costs of Production

10.2.3.2 Soaring Vaccines Demand from Developing Countries

10.2.4 Political Factors

10.2.4.1 Governments Play Crucial Roles in Vaccination

11. Conclusions

11.1 Segment Market Share Shift

11.2 Elderly People Become the New Target Market

11.3 Endemic Infections Drive Travel Vaccines Growth

11.4 Emerging Markets: High Demand for Vaccines

11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth

11.6 Strong and Diverse Research and Development

11.7 Concluding Remarks

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2019-2029

Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), AGR (%), CAGR (%), 2019-2029

Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2029

Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.1 Prevnar Revenue ($bn), 2014-2017

Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.3 Gardasil Revenue ($bn), 2014-2017

Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2017

Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.7 Pentacel Revenue ($bn), 2014-2017

Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2014-2017

Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016

Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.13 Zostavax Revenue ($bn), 2014-2017

Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.15 RotaTeq Revenue ($bn), 2014-2017

Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016

Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029

Table 5.19 Menactra Revenue ($bn), 2014-2017

Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029

Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2023, 2029

Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2023, 2029

Table 6.3 Leading Developed National Market Shares (%), 2018, 2023, 2029

Table 6.4 North America Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%) and CAGR (%), 2019-2029

Table 6.5 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029

Table 6.6 The US Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 6.7 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.8 Europe Vaccines Revenue Forecast by Submarkets ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.9 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2019-2029

Table 6.10 The EU5 Vaccines World Market Shares (%), 2018, 2023, 2029

Table 6.11 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.12 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.13 The French Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.14 The German Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.15 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 6.16 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.1 Asia-Pacific Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.2 Asia-Pacific Vaccines Revenue Forecast, By Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029

Table 7.3 Leading Emerging National Market Revenue Forecasts ($bn), 2018, 2023, 2029

Table 7.4 Leading Emerging National Market Shares (%), 2018, 2023, 2029

Table 7.5 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029

Table 7.6 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 7.7 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029

Table 7.8 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share and CAGR (%), 2019-2029

Table 9.1 Prophylactic Vaccines in Development, 2018

Table 9.2 Paediatric Vaccines in Development, 2018

Table 9.3 Adult Vaccines in Development, 2018

Table 9.4 Elderly Vaccines in Development, 2018

Table 9.5 Travel Vaccines in Development, 2018

Table 9.6 Therapeutic Vaccines in Development, 2018

List of Figures

Figure 1.1 World Vaccines Market Segmentation, 2017

Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018

Figure 3.2 World Vaccines Leading National Market Shares (%), 2018

Figure 3.3 World Vaccines Leading National Market Shares (%), 2023

Figure 3.4 World Vaccines Leading National Market Shares (%), 2029

Figure 3.5 World Vaccines Market: Drivers and Restraints

Figure 4.1 World Vaccines Submarket (%) Segmentation, 2018

Figure 4.2 World Paediatric Vaccines Market Share (%), 2019

Figure 4.3 World Paediatric Vaccines Market Share (%), 2023

Figure 4.4 World Paediatric Vaccines Market Share (%), 2029

Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.6 World Adult Vaccines Market Share (%), 2019

Figure 4.7 World Adult Vaccines Market Share (%), 2023

Figure 4.8 World Adult Vaccines Market Share (%), 2029

Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.10 World Elderly Vaccines Market Share (%), 2019

Figure 4.11 World Elderly Vaccines Market Share (%), 2023

Figure 4.12 World Elderly Vaccines Market Share (%), 2029

Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2019-2029

Figure 4.14 World Travel Vaccines Market Share (%), 2019

Figure 4.15 World Travel Vaccines Market Share (%), 2023

Figure 4.16 World Travel Vaccines Market Share (%), 2029

Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2019-2029

Figure 5.1 Prevnar Revenue Forecast ($bn), 2019-2029

Figure 5.2 Gardasil Revenue Forecast ($bn), 2019-2029

Figure 5.3 Fluzone Revenue Forecast ($bn), 2019-2029

Figure 5.4 Pentacel Revenue Forecast ($bn), 2019-2029

Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2019-2029

Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2019-2029

Figure 5.7 Zostavax Revenue Forecast ($bn), 2019-2029

Figure 5.8 RotaTeq Revenue Forecast ($bn), 2019-2029

Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2019-2029

Figure 5.10 Menactra Revenue Forecast ($bn), 2019-2029

Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.3 EU5 Vaccines Market Share (%), 2018

Figure 6.4 EU5 Vaccines Market Share (%), 2023

Figure 6.5 EU5 Vaccines Market Share (%), 2029

Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.1 BRIC Countries Vaccines Market Share (%), 2018

Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2023

Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2029

Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2019-2029

Figure 8.1 GSK Vaccines Revenue ($bn), 2015-2017

Figure 8.2 GSK Vaccines Region Breakdown (%), 2017

Figure 8.3 Merck Vaccines Revenue (%), 2017

Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017

Figure 8.5 Pfizer Revenue ($bn), 2014-2017

Figure 8.6 J&J Revenue ($bn), 2014-2017

Figure 8.7 AstraZeneca Revenue ($bn), 2014-2017

Figure 8.8 Eli Lilly and Company Revenue ($bn), 2014-2017

Figure 8.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017

Figure 10.1 SWOT Analysis of the World Vaccines Market

Figure 10.2 STEP Analysis of the World Vaccines Market

Figure 11.1 World Paediatric Vaccines Revenue Forecast ($bn), 2018-2029

Figure 11.2 World Elderly Vaccines Revenue Forecast ($bn), 2018-2029

Figure 11.3 Asia-Pacific Vaccines Revenue Forecast (% Share), 2018-2029